...
首页> 外文期刊>Clinical Cancer Investigation Journal >Primary parotid B-cell lymphoma successfully treated with chemotherapy plus highly active antiretroviral therapy with prolonged survival and immune reconstitution in an acquired immunodeficiency syndrome patient: Case report and review of the literature
【24h】

Primary parotid B-cell lymphoma successfully treated with chemotherapy plus highly active antiretroviral therapy with prolonged survival and immune reconstitution in an acquired immunodeficiency syndrome patient: Case report and review of the literature

机译:原发性腮腺B细胞淋巴瘤通过化学疗法加高活性抗逆转录病毒疗法成功治疗,获得性免疫缺陷综合征患者:生存期延长和免疫重建:病例报告和文献复习

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Non-Hodgkin's lymphoma (NHL) is the second most common acquired immunodeficiency syndrome (AIDS)-defining cancer. In this population, up to 70-80% of cases may present as extranodal location as the primary clinical manifestation of the neoplasm disease. Gastrointestinal tract is the most frequent location of AIDS-associated NHL. However, salivary gland involvement, including the parotid gland is a rare complication in human immunodeficiency virus (HIV)-patients. Here, we describe a patient seropositive for the HIV, who developed a primary NHL of the parotid gland histologically classified as a high-grade diffuse large B-cell lymphoma. Patient was treated with a combination of chemotherapy plus highly active antiretroviral therapy with a good clinical, virological and immunological response and a prolonged survival, more than 5 years, without evidence of neoplasm relapse.
机译:非霍奇金淋巴瘤(NHL)是第二大最常见的获得性免疫缺陷综合症(AIDS)定义癌症。在这一人群中,多达70-80%的病例可能以结外位置的形式出现,成为肿瘤疾病的主要临床表现。胃肠道是与艾滋病相关的非霍奇金淋巴瘤最常见的位置。然而,唾液腺(包括腮腺)受累是人类免疫缺陷病毒(HIV)患者的罕见并发症。在这里,我们描述了一名患者的HIV血清阳性,该患者发展成腮腺的原发性NHL,在组织学上被分类为高度弥漫性大B细胞淋巴瘤。患者接受了化学疗法加高活性抗逆转录病毒疗法的联合治疗,具有良好的临床,病毒学和免疫学应答,并且生存期延长了5年以上,而没有肿瘤复发的迹象。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号